



SEMPERIT GROUP H1 2019/Q2 2019 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Frank Gumbinger, CFO

14 August 2019



Agenda

Highlights (p.3)

Operational highlights (p.6)

Financial performance (p.13)


Management agenda (p.22)

Appendix (p.25)



Transformation programme gathering pace, with Group performance strongly above H1 2018 at both EBITDA / EBIT level

- Reduced complexity and higher quality of order book
- Target profitability of 10% EBITDA margin by end of 2020 (run rate 2021)



- Revenue –2.5% for Group
 - -0.7% for Industrial Sector
 - -5.9% for Medical Sector
- EBITDA +19.5% for Group
 - +26.2% for Industrial Sector
 - Medical Sector with negative EBITDA (though turning positive in Q2'19)
 - 9.0% EBITDA margin
- EBIT € 20.9m vs. adj. € 13.2m H1'18
 - 4.8% EBIT margin vs. adj. 2.9% H1'18

¹⁾ H1'18 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.



Highlights H1 2019



- **Revenue decreased by 2.5% to € 437.3m**
 - Industrial Sector almost flat (-0.7% to € 289.5m)
 - Medical Sector declined by 5.9% to € 147.8m



- **Semperit Group continues to improve at EBITDA and EBIT level**
 - Profitability significantly increased in H1'19 and Q2'19
 - Increase of year-on-year profitability for 6th consecutive quarter
 - All four segments profitable, Sempermed returns to profitability at EBITDA level



- **EBITDA € 39.1m, +19.5% vs. adj. € 32.7m H1'18,**
EBITDA margin 9.0% vs. 7.3% H1'18,
- **EBIT € 20.9m vs. adj. € 13.2m H1'18,**
EBIT margin 4.8% vs. adj. 2.9% H1'18



- **Net profit € 5.8m vs. € -67.4m in H1'18**
- **Capex € 21.4m vs. € 42.1m in H1'18**



- **Focus points**
 - SemperMove10 delivers results
 - Preparation for the approaching slowdown of the global economy
 - Strategy project SemperGrowth200 has been started; details will be presented at the end of 2019 at the earliest
 - Extension of digital connection to our customers increases order processing speed



Agenda

Highlights (p.3)

Operational highlights (p.6)

Financial performance (p.13)


Management agenda (p.22)

Appendix (p.25)



Revenue development H1 2019

in € m



Revenue development

- **Semperfex:** Revenue at similar level as H1'18 despite reduced market demand and economic uncertainty.
- **Sempertrans:** Revenue decrease due to shift of focus from maximum production utilisation to order and product profitability
- **Semperform:** Slight increase of revenue paired with significant improvement of profitability
- **Sempermed:** Lower sales due to less traded gloves

¹⁾ All percentage numbers imply year-on-year percentage change for H1'2019.




Industrial Sector H1 and Q2 2019



¹⁾ H1'2018 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.




Semperflex H1 2019



Semperflex



H1 2019 vs. H1 2018



- Revenue and profitability at similar level as H1'18
- Reduced market demand due to destocking within supply chain and uncertainty of future market development
- Size of order book decreased compared to H1'18
- Buyers market – competitive pressure expected to increase further






Sempertrans H1 2019

H1'18 vs H1'19: >100% EBITDA yoy, € 6.8m

Sempertrans



H1 2019 vs. H1 2018

Revenue current period	68
Revenue previous period	72
EBITDA current period	8
EBITDA ¹⁾ previous period	1

in € m

- Successful turnaround continuing after challenging closure of Sempertrans sites in France and China
- Significant improvement of profitability mainly due to higher order quality
- Strong operational improvement
- EBITDA in H1'19 includes € 1.3m profit from sale of assets of closed factory in China




¹⁾ H1'2018 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.




Semperform H1 2019

H1'18 vs H1'19: +36.1% EBITDA yoy, € 4.3m

Semperform



H1 2019 vs. H1 2018



- Solid order book and capacity utilisation against the backdrop of an increasingly challenging economic environment
- Implementation of SemperMove10 programme supports EBITDA uplift compared to H1'18
- Diversified product portfolio, with Profile accounting for 50% of revenues but being exposed to sluggish construction market







Medical Sector / Sempermed segment H1 2019

Medical Sector

Sempermed



H1 2019 vs. H1 2018



- Revenue decline mainly driven by lower traded goods and due to strategic transition to Nitrile
- Positive order intake development compared to previous period
- Operational improvements beginning to show positive effects in Q2'19
- First positive EBITDA since four quarters





Agenda

Highlights update (p.3)

Operational highlights (p.6)

Financial performance (p.13)

Management agenda (p.22)

Appendix (p.25)



Financials and Profitability Overview

Key figures Semperit Group H1 2019				
in EUR m	H1 2019	H1 2018	Change	Change in EUR m
Revenue	437.3	448.5	-2.5%	-11.2
EBITDA adjusted¹⁾	39.1	32.7	+19.5%	+6.4
EBITDA margin adjusted	9.0%	7.3%	+1.7 PP	–
EBITDA	39.1	28.9	+35.5%	10.3
EBITDA margin	9.0%	6.4%	+2.6 PP	–
EBIT adjusted¹⁾	20.9	13.2	+58.5%	–
EBIT margin adjusted	4.8%	2.9%	+1.8 PP	–
EBIT	20.9	-49.8	–	70.7
EBIT margin	4.8%	-11.1%	+15.9 PP	–
Earnings after tax	5.8	-67.4	–	73.2
Earnings per share (EPS)²⁾, in EUR	0.28	-3.33	–	–


¹⁾ H1 2018 figures adjusted for negative one-off effect of € 55m from impairment at Sempermed (adj. for EBIT and EAT only) and € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China.

²⁾ Earnings per share are solely attributable to the ordinary shareholders of Semperit AG Holding (excl. interest from hybrid capital).



Revenue development H1 2019

in € m




¹⁾ All percentage numbers imply year-on-year percentage change for H1'2019.



EBITDA development H1 2019


in € m



¹⁾ H1'2019 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.



Consistent yoy EBITDA improvement for 6th consecutive quarter



- Continuous improvements for EBITDA for three quarters in a row
- Second half of the year / third and fourth quarter in general weaker due to seasonality


¹⁾ H1'2019 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.



Investments by quarter

- FY 2018: overall Capex of € 81m, approx. 50% for Semperflex and mixing
- FY 2019: overall Capex of € about 40m planned

CAPEX per segment in € m






Working Capital Overview

Components of Working Capital

in € m




¹⁾ Trade Working Capital in % of LTM revenues



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 30/06/2019: € 815m
Balance sheet 31/12/2018: € 769m



Financial profile as of 30 June 2019


- Cash and cash equivalents of € 155m
- Financial liabilities:
 - Corporate Schuldschein loan of € 226m
 - Liabilities to banks of € 8m
- Net debt of € 78.8m
 - down by € 33.9m since end of Dec. 2018
 - Net debt / EBITDA of 1.4x, compared to 2.4x as of end of Dec. 2018
- Hybrid capital of € 130.0m strengthens equity
- Equity ratio of 41.4% vs. 42.9% Dec. 2018



Financial Policy Framework

no change since Q1'19

Focus on Value Management



- EBITDA margin of **10%** at Group level by end of 2020 (run rate 2021)



- Equity ratio of **>30%**



- Net debt/EBITDA **< 3.5x**



- Working Capital to revenue **< 25%**, focus to stay closer to **20%**¹⁾



- Total Capex of about € 40m in FY 2019
 - mostly for maintenance

¹⁾ Working capital to last twelve months revenue.



Agenda

Restructuring and Transformation update (p.3)

Operational highlights (p.6)

Financial performance (p.13)

Management agenda (p.22)

Appendix (p.25)




Management agenda 2019

Focus on SemperMOVE10 to reach 10% EBITDA margin at Group level by end of 2020 (run rate 2021)



Operations initiatives

- Increase output / Overall Equipment Effectiveness (OEE)
- Production footprint
- Inventory management
- Reduce waste and scrap
- Total cost of quality



Sales initiatives

- Volume growth (new markets, new regions)
- Customer benefits/value, price differentiation by region
- Brand leverage



Procurement, SG&A initiatives

- Sustainable customer/supplier relationship
- Optimise compound chemicals
- Backoffice and IT efficiency

Investments

- Overall Capex of about € 40m for FY 2019
 - further reduction to support FCF generation
 - mostly for maintenance
 - half the amount of FY 2018

Potential adverse external effects

- Additional capacities from competitors to come on stream / excess production capacities
- Risk of economic recession, further trade disputes
- So far no significant impact in current trading

Financial impact

- Positive free cash flow
- Gradual improvement at EBITDA level



Contact and financial calendar

Investor Relations Semperit

Agnes Springer, Investor Relations

+43 1 79777 - 213

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2019

14.08.2019 Half-year financial report 2019

21.11.2019 Report Q1-3 2019

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete.
Statements referring to people are valid for both men and women.



Agenda

Restructuring and Transformation update (p.3)

Operational highlights (p.6)

Financial performance (p.13)

Management agenda (p.22)

Appendix (p.25)



Financials and Profitability Overview Q2 2019 vs. Q2 2018


Key figures Semperit Group Q2 2019				
in EUR m	Q2 2019	Q2 2018	Change	Change in EUR m
Revenue	224.4	227.6	-1.4%	-3.3
EBITDA adjusted¹⁾	22.7	17.0	+33.4%	+5.7
EBITDA margin adjusted	10.1%	7.5%	+2.6 PP	
EBITDA	22.7	13.1	+72.7%	9.5
EBITDA margin	10.1%	5.8%	+4.3 PP	
EBIT adjusted¹⁾	13.1	7.2	+81.5%	+5.9
EBIT margin adjusted	5.8%	3.2%	+2.7 PP	
EBIT	13.1	-55.8	–	68.9
EBIT margin	5.8%	-24.5%	+30.3 PP	
Earnings after tax	2.6	-64.8	–	67.4

¹⁾ Attributable to the shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.




From reported to operating EBITDA / EBIT H1 2018

in EUR m



Reported EBITDA H1 2018 Expense for closure of Sempertans site in China **Adj. EBITDA H1 2018**




Reported EBIT H1 2018 Impairment Sempermed Expense for closure of Sempertans site in China **Adj. EBIT H1 2018**



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable

Price indices Butadiene as main raw material for synthetic rubber / latex




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2016 = 100




Overview price indices carbon black / wire rod

Significant increase for raw materials¹⁾ used in industrial segments

Price index carbon black



Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2016 = 100




Hybrid Capital Line with B & C

- **Overview**

- Contract between Semperit AG Holding and B & C Holding GmbH (100% subsidiary of B & C Industrieholding GmbH) signed on 12th Dec. 2017, total volume of up to € 150m
- Can be drawn in up to three tranches until end of 2019
- Interest rate agreed amounts to 5.25%, commitment fee (for unused part of the line) is set at 1.75%
- € 130m drawn in March 2018

- **Benefits for Semperit**

- Financial support for transformation process
- Strengthening of balance sheet



The core shareholder supports the transformation process and emphasises its long-term commitment to Semperit.



Sectors and Group: H1 2019 vs H1 2018

in EUR m	Industrial Sector				Medical Sector				Semperit Group ¹⁾			
	H1 2019	H1 2018	%	Change in EUR m	H1 2019	H1 2018	%	Change in EUR m	H1 2019	H1 2018	%	Change in EUR m
Revenue	289.5	291.4	-0.7%	-1.9	147.8	157.1	-5.9%	-9.3	437.3	448.5	-2.5%	-11.2
EBITDA	52.7	37.9	+39.0%	14.8	-0.3	0.1	–	-0.4	39.1	28.9	+35.5%	10.2
EBITDA margin	18.2%	13.0%	+5.2 PP	–	-0.2%	0.1%	-0.3 PP	–	9.0%	6.4%	+2.6 PP	–
Adj. EBITDA	52.7	41.8	+26.2%	10.9	-0.3	0.1	–	-0.4	39.1	32.7	+19.5%	6.4
Adj. EBITDA margin	18.2%	14.3%	+3.9 PP	–	-0.2%	0.1%	-0.3 PP	–	9.0%	7.3%	+1.7 PP	–
EBIT	39.5	22.6	+74.7%	16.9	-4.2	-62.5	-93.2%	58.3	20.9	-49.8	–	70.7
EBIT margin	13.6%	7.8%	+5.8 PP	–	-2.9%	-39.8%	+36.9 PP	–	4.8%	-11.1%	+15.9 PP	–
Adj. EBIT	39.5	30.5	+29.6%	9.0	-4.2	-7.3	-42.0%	3.1	20.9	13.2	+58.5%	7.7
Adj. EBIT margin	13.6%	10.5%	+3.2 PP	–	-2.9%	-4.6%	+1.7 PP	–	4.8%	2.9%	+1.8 PP	–
Earnings after tax	–	–	–	–	–	–	–	–	–	–	–	–
Earnings per share in EUR	–	–	–	–	–	–	–	–	–	–	–	–
Investments	21.4	33.5	-36.1%	-12.1	3.2	8.0	-60.7%	-4.80	21.4	42.1	-49.2%	-20.7
Employees	3,691	3,745	-1.5%	–	3,319	3,008	+10.4%	–	7,147	6,874	+4.0%	–

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects), reported figures: EBITDA: € -7.1m in Q1 2019 (€ -4.3m in Q1 2018), EBIT € -7.7m (€ -4.9m).



Sectors and Group: Q2 2019 vs Q2 2018

in EUR m	Industrial Sector				Medical Sector				Semperit Group ¹⁾			
	Q2 2019	Q2 2018	%	Change in EUR m	Q2 2019	Q2 2018	%	Change in EUR m	Q2 2019	Q2 2018	%	Change in EUR m
Revenue	148.0	150.5	-1.7%	-2.5	76.4	77.1	-0.9%	-0.7	224.4	227.6	-1.4%	-3.2
EBITDA	28.2	19.1	+47.2%	9.1	0.6	-1.3	–	1.9	22.7	13.1	+72.7%	9.6
EBITDA margin	19.0%	12.7%	+6.3 PP	–	0.8%	-1.7%	+2.5 PP	–	10.1%	5.8%	+4.3 PP	–
Adj. EBITDA	28.2	23.0	+22.5%	5.2	0.6	-1.3	–	1.9	22.7	17.0	+33.4%	5.7
Adj. EBITDA margin	19.0%	15.3%	+3.8 PP	–	0.8%	-1.7%	+2.5 PP	–	10.1%	7.5%	+2.6 PP	–
EBIT	21.1	9.5	–	11.6	-1.4	-60.3	-97.6%	58.9	13.1	-55.8	–	68.9
EBIT margin	14.3%	6.3%	+8.0 PP	–	-1.9%	-78.2%	+76.3 PP	–	5.8%	-24.5%	+30.3 PP	–
Adj. EBIT	21.1	17.4	+21.4%	3.7	-1.4	-5.1	-72.0%	3.7	13.1	7.2	+81.5%	5.9
Adj. EBIT margin	14.3%	11.6%	+2.7 PP	–	-1.9%	-6.6%	+4.7 PP	–	5.8%	3.2%	+2.6 PP	–
Earnings after tax	–	–	–	–	–	–	–	–	–	–	–	–
Earnings per share in EUR	–	–	–	–	–	–	–	–	–	–	–	–
Investments	3.4	15.5	-78.1%	-12.1	1.8	1.6	+12.5%	0.2	5.2	17.6	–	-12.4
Employees	3,691	3,745	-1.5%	–	3,319	3,008	+10.4%	–	7,147	6,874	+4.0%	–

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects), reported figures: EBITDA: € -7.1m in Q1 2019 (€ -4.3m in Q1 2018), EBIT € -7.7m (€ -4.9m).




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2016 adj. ¹⁾	Q1 2017 adj. ²⁾	Q2 2017 adj. ²⁾	Q3 2017 adj. ²⁾	Q4 2017 adj. ²⁾	FY 2017 adj. ²⁾	Q1 2018	Q2 2018 adj. ³⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019
Revenue	852.4	229.3	232.3	208.4	204.2	874.2	220.9	227.6	221.7	208.2	878.5	212.9	224.4
EBITDA	74.7	9.6	12.9	10.4	2.9	35.8	15.8	17.0	13.1	4.5	50.3	16.5	22.7
EBITDA margin	8.8%	4.2%	5.6%	5.0%	1.4%	4.1%	7.1%	7.5%	5.9%	2.2%	5.7%	7.7%	10.1%
EBIT	41.1	1.6	4.6	1.7	-8.7	-0.8	6.0	7.2	4.3	-2.2	15.4	7.8	13.1
EBIT margin	4.8%	0.7%	2.0%	0.8%	-4.3%	-0.1%	2.7%	3.2%	1.9%	-1.0%	1.7%	3.7%	5.8%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Figures for 2016 without profit contribution from SSC and adj. for JV transaction.

²⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 adj. for impairment at Sempermed (€ 26m adj. for EBIT only), restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).

³⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only).



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

	FY 2016 ¹⁾	Q1 2017	Q2 2017	Q3 2017 adj. ²⁾	Q4 2017	FY 2017 adj. ²⁾	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019
in EUR m													
Revenue	184.9	53.5	53.2	46.8	52.5	206.1	58.8	62.8	53.4	55.1	230.0	61.1	59.7
EBITDA	43.4	11.7	10.5	8.7	10.5	41.4	13.7	14.9	9.3	10.9	48.9	13.9	14.5
EBITDA margin	23.5%	21.8%	19.8%	18.6%	19.9%	20.1%	23.4%	23.8%	17.4%	19.8%	21.3%	22.8%	24.3%
EBIT	35.3	9.6	8.6	6.8	7.8	32.7	11.1	12.3	6.9	8.1	38.4	11.1	11.5
EBIT margin	19.1%	18.0%	16.1%	14.5%	14.8%	15.9%	18.9%	19.7%	12.9%	14.8%	16.7%	18.2%	19.2%

Sempertrans (Conveyor belts)

	FY 2016	Q1 2017	Q2 2017 adj. ³⁾	Q3 2017 adj. ³⁾	Q4 2017 adj. ³⁾	FY 2017 adj. ³⁾	Q1 2018	Q2 2018 adj. ⁴⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019
in EUR m													
Revenue	148.4	41.3	36.8	35.7	32.1	146.0	34.6	37.0	37.6	35.5	144.8	30.4	37.8
EBITDA	15.9	0.6	-2.4	-1.4	-2.1	-5.3	0.5	0.8	2.4	0.7	4.4	2.7	5.4
EBITDA margin	10.7%	1.4%	-6.4%	-3.9%	-6.6%	-3.6%	1.4%	2.1%	6.4%	2.1%	3.0%	9.0%	14.2%
EBIT	12.1	-0.3	-3.3	-2.2	-3.0	-8.9	-0.4	-0.1	1.6	-0.4	0.7	1.8	3.8
EBIT margin	8.2%	-0.8%	-8.9%	-6.3%	-9.6%	-6.1%	-1.1%	-0.2%	4.3%	-1.1%	0.5%	6.0%	10.0%

¹⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform.

²⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 1m)

³⁾ Adj. for restructuring expenses/closing in France (€ 11m)

⁴⁾ Adj. for € 4m (EBITDA) / € 8m (EBIT) from closure of Sempertrans site in China.



Semperform and Sempermed (adj. where applicable)

Semperform (Window and door profiles, Handrails)

	FY 2016 ¹⁾	Q1 2017	Q2 2017	Q3 2017 adj. ⁴⁾	Q4 2017	FY 2017 adj. ⁴⁾	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019
in EUR m													
Revenue	173.1	45.3	50.1	46.9	42.7	185.0	47.5	50.7	50.3	43.7	192.2	49.9	50.5
EBITDA	30.2	5.0	7.8	5.2	3.6	21.5	4.5	7.3	6.2	3.9	21.9	7.9	8.3
EBITDA margin	17.4%	10.9%	15.5%	11.0%	8.5%	11.6%	9.6%	14.4%	12.2%	8.9%	11.4%	15.7%	16.4%
EBIT	22.5	3.0	5.8	3.2	1.3	13.3	2.4	5.1	4.2	1.5	13.2	5.4	5.9
EBIT margin	13.0%	6.6%	11.5%	6.8%	3.0%	7.2%	5.0%	10.1%	8.4%	3.4%	6.9%	10.9%	11.6%

Sempermed (Gloves)

	FY 2016 adj. ²⁾	Q1 2017 adj. ³⁾	Q2 2017 adj. ³⁾	Q3 2017 adj. ⁴⁾	Q4 2017	FY 2017 adj. ^{3) 4)}	Q1 2018	Q2 2018 adj. ⁵⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019
in EUR m													
Revenue	346.0	89.2	92.2	78.8	76.9	337.1	80.0	77.1	80.4	73.9	311.5	71.5	76.4
EBITDA	3.4	0.0	1.7	1.6	-1.5	1.8	1.4	-1.3	-0.9	-3.1	-3.9	-0.9	0.6
EBITDA margin	1.0%	±0.0%	1.9%	2.0%	-2.0%	0.5%	1.8%	-1.7%	-1.1%	-4.2%	-1.3%	-1.2%	0.8%
EBIT	-10.1	-2.8	-1.2	-1.5	-6.7	-12.1	-2.2	-5.1	-3.9	-3.1	-14.3	-2.8	-1.4
EBIT margin	-2.9%	-3.1%	-1.3%	-1.8%	-8.6%	-3.6%	-2.8%	-6.6%	-4.8%	-4.2%	-4.6%	-3.9%	-1.9%

¹⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

²⁾ Adj. for negative one-off effects in Q4 2016 and without profit contribution from SSC for FY 2016

³⁾ Q1 2017 Sempermed adj. for positive one-off effects from JV transaction of € 78m for EBITDA/EBIT; Q2 2017 adj. for impairment at Sempermed (€ 26m, EBIT only).

⁴⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 2m for Semperform, € 2m for Sempermed)

⁵⁾ Adj. for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT only)



Sectors and Group: FY 2018 vs FY 2017

in EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	FY 2018	FY 2017	%	FY 2018	FY 2017	%	FY 2018	FY 2017	%
Revenue	567.0	537.0	+5.6%	311.5	337.1	-7.6%	878.5	874.2	+0.5%
EBITDA	71.3	42.9	+66.1%	-3.9	77.9	-	46.4	100.2	-53.7%
EBITDA margin	12.6%	8.0%	+4.6 PP	-1.3%	23.1%	-24.4 PP	5.3%	11.5%	-6.2 PP
Adj. EBITDA²⁾	75.2	57.6	+30.6%	-3.9	1.8	-	50.3	35.8	+40.6%
Adj. EBITDA margin ²⁾	13.3%	10.7%	+2.5 PP	-1.3%	0.5%	-1.8 PP	5.7%	4.1%	+1.6 PP
EBIT	44.6	22.4	+98.7%	-69.6	38.0	-	-47.7	37.6	-
EBIT margin	7.9%	4.2%	+3.7 PP	-22.3%	11.3%	-33.6 PP	-5.4%	4.3%	-9.7 PP
Adj. EBIT²⁾	52.4	37.1	+41.4%	-14.3	-12.1	18.4%	15.4	-0.8	-
Adj. EBIT margin ²⁾	9.2%	6.9%	+2.3 PP	-4.6%	-3.6%	-1.0 PP	1.7%	-0.1%	+1.8 PP
Earnings after tax	-	-	-	-	-	-	-80.4	-26.3	>100%
Adj. Earnings after tax²⁾	-	-	-	-	-	-	-17.3	-43.3	-60.0%
Earnings per share in EUR	-	-	-	-	-	-	-4.13	-1.25	>100%
Adj. Earnings per share in EUR	-	-	-	-	-	-	-1.07	-2.11	-49.4%
Investments	67.0	48.5	+38.2%	12.7	25.3	-49.7%	80.8	74.5	+8.6%
Employees	3,654	3,648	+0.2%	2,979	3,051	-2.4%	6,773	6,838	-1.0%

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects), reported figures: EBITDA: € -21.0m in FY 2018 (€ -20.6m in FY 2017), EBIT € -22.7m (€ -22.8m).

²⁾ FY 2018 adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only), € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China. FY 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for EAT) and negative one-off effects from impairment at Sempermed (€ 26m adj. for EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ³⁾ Attributable to the shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.



Key figures 2008-2018

Key performance figures											
in EUR m	2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾
Revenue	655.3	588.1	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5
EBITDA	87.9	102.8	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3
EBITDA margin	13.4%	17.5%	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%
EBIT	58.7	69.6	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4
EBIT margin	9.0%	11.8%	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%
Earnings after tax	44.9	38.8	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3
EPS²⁾, in EUR	1.83	1.89	2.21	2.52	2.25	2.65	1.85	2.26	0.74	-2.13	-1.07
Gross cash flow	78.0	92.6	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4
Return on equity	12.9%	12.5%	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%

Balance sheet key figures											
in EUR m	2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018
Balance sheet total	485.5	531.5	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8
Equity²⁾	291.9	310.6	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5
Equity ratio	60.1%	58.4%	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%
Investments in tangible and intangible assets	27.6	22.7	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8
Employees, at balance sheet date, FTEs	7,064	6,649	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated. ²⁾ Attributable to shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital. ³⁾ 2014 and 2015 restated. ⁴⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁵⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁶⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only).



Product / market position / segment overview, FY 2018

Semperit Group

Group	Industrial Sector			Medical Sector	
	Semperflex	Sempertrans	Semperform	Sempermed	
Revenue	€ 878m	€ 230m / 26% ¹⁾	€ 145m / 17% ¹⁾	€ 192m / 22% ¹⁾	€ 312m / 35% ¹⁾
EBITDA adj.	€ 50m ²⁾	€ 49m	€ 4m	€ 22m	€ -4m
Employees	6,773 ²⁾	1,776 / 27% ³⁾	878 / 13% ³⁾	1000 / 15% ³⁾	2,979 / 44% ³⁾

Products and market position


Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe



Conveyor belts

One of the leading providers for heavy duty steel and textile cord belts



Profiles / Handrails

Leading position in construction (**profiles, piping, gaskets**) and infrastructure (**handrails, sheave liners, rail track**) business with European focus



Examination gloves

Among the top 10 glovemakers in the world



Surgical gloves

Leading position in Europe



¹⁾ Revenue in % of Group revenue.


²⁾ Group figure includes corporate center of € -21m, 140 employees.

³⁾ Employees in % of Group employees.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C